What Is Resistant Hypertension and Why It Won't Drop

When Three Drugs Are Not Enough

Most people with high blood pressure can bring their numbers down with one or two medications. But for a stubborn subset of patients, blood pressure remains dangerously elevated despite taking three or more antihypertensive drugs at maximum tolerated doses, including a diuretic. Doctors call this condition resistant hypertension, and it affects roughly 7 to 10 million Americans—about 12–13% of everyone treated for high blood pressure.

Resistant hypertension is not merely an inconvenience. Patients face significantly higher risks of heart attack, stroke, heart failure, and chronic kidney disease compared with those whose blood pressure responds to standard treatment. Understanding why some cases refuse to budge—and what hidden causes lurk beneath them—is increasingly important as new research reshapes how clinicians approach the problem.

How Doctors Define It

The American Heart Association defines resistant hypertension as blood pressure that remains above the goal of 130/80 mmHg despite concurrent use of three antihypertensive agents of different classes, one of which must be a diuretic. A patient whose pressure is controlled but requires four or more drugs also qualifies. The definition excludes so-called pseudo-resistance—cases where blood pressure readings are falsely high due to improper cuff technique, white-coat syndrome, or patients simply not taking their pills.

That last factor is surprisingly common. Studies cited by the Cleveland Clinic estimate that medication non-adherence explains up to 40% of apparent treatment-resistant cases. Before diagnosing true resistance, physicians must verify that patients are actually taking their medications and measuring blood pressure correctly.

The Usual Suspects

Once non-adherence is ruled out, clinicians investigate secondary causes—underlying conditions that drive blood pressure up independently of the primary hypertension. The most common culprits include:

• Obstructive sleep apnea — repeated nighttime breathing pauses trigger stress hormones that raise pressure
• Primary aldosteronism — the adrenal glands produce too much aldosterone, causing sodium retention
• Chronic kidney disease — impaired kidneys struggle to regulate fluid and salt balance
• Renal artery stenosis — narrowed arteries supplying the kidneys reduce blood flow, prompting the body to raise pressure

Lifestyle factors also play a role. Excess sodium intake, heavy alcohol use, obesity, and regular use of non-steroidal anti-inflammatory drugs (NSAIDs) can all blunt the effectiveness of antihypertensive medications, according to Johns Hopkins Medicine.

The Cortisol Connection

A cause that has historically flown under the radar is hypercortisolism—excess production of the stress hormone cortisol. The MOMENTUM trial, the largest study of its kind in the United States, screened 1,086 patients with resistant hypertension across 50 medical centers. The results, presented at the American College of Cardiology's 2026 Scientific Session, were striking: 27% of participants had biochemical evidence of hypercortisolism.

An additional 20% had primary hyperaldosteronism, and 6% had both conditions simultaneously. Lead investigator Dr. Deepak L. Bhatt emphasized that these findings should prompt broader screening for hormonal disorders in patients whose blood pressure resists conventional therapy.

Excess cortisol raises blood pressure through multiple mechanisms: it increases sodium retention, boosts the sensitivity of blood vessels to constricting signals, and promotes insulin resistance—all of which compound hypertension. Yet routine cortisol testing is not standard practice in hypertension workups, meaning many patients may go years without the correct diagnosis.

Treatment and the Path Forward

Managing resistant hypertension begins with optimizing the basics: confirming adherence, reducing sodium below 2,400 milligrams per day, limiting alcohol, increasing aerobic exercise, and discontinuing medications that raise blood pressure. When secondary causes are identified, targeted treatments—such as mineralocorticoid receptor antagonists for aldosteronism or CPAP therapy for sleep apnea—can dramatically improve control.

For cortisol-driven cases, the therapeutic landscape is evolving. Cortisol-modulating drugs already approved for Cushing syndrome may eventually be repurposed, though randomized trials are still needed to confirm their benefit in the broader resistant hypertension population.

The core message for patients and physicians alike is straightforward: when blood pressure will not drop, the answer may not be another pill—it may be a hormone test that was never ordered.